Hypertrophic Cardiomyopathy Market Size in the 7MM is estimated to Increase by 2032 | Novartis, Imbria Pharmaceuticals, Cytokinetics, MyoKardia, Ji Xing Pharmaceuticals (Shanghai) Co. Ltd, Bristol-Myers Squibb, and others.

{Delhi, India}, To strategically aid Hypertrophic Cardiomyopathy companies in developing drugs for Hypertrophic Cardiomyopathy, DelveInsight launched a report titled “Hypertrophic Cardiomyopathy Market Insight Epidemiology and Market Forecast 2032”. This comprehensive report delves into epidemiology-based market analysis, providing a roadmap for success in the dynamic landscape of the Hypertrophic Cardiomyopathy Market.

Download a free sample report of the “Hypertrophic Cardiomyopathy Market”

Key Takeaways from the Hypertrophic Cardiomyopathy Market Research Report

• Multiple new Hypertrophic Cardiomyopathy drugs are going through different phases of clinical trials; these upcoming therapies are expected to be a better treatment option for HCM. The expected launch of therapies and the increasing prevalence are expected to lead to market growth during the forecast period (2023-2032).
• In the epidemiology forecast model of DelveInsight, in 2022, EU4 and the UK accounted for 120,389 diagnosed prevalent cases, which is estimated to increase during the forecast period (2023–2032).
• The leading Hypertrophic Cardiomyopathy companies working in the market include Novartis, Imbria Pharmaceuticals, Cytokinetics, MyoKardia, Ji Xing Pharmaceuticals (Shanghai) Co. Ltd, Bristol-Myers Squibb, Shandong Suncadia Medicine Co., Ltd., MyoKardia Inc., Medtronic, GE Healthcare, Abbott Medical Devices, Tenaya Therapeutics, LianBio LLC, Gilead Sciences, LianBio LLC, Novartis Pharmaceuticals, iRhythm Technologies Inc., Amicus Therapeutics, Tau Pnu Medical Co. Ltd, Rocket Pharmaceuticals Inc., Edwards Lifesciences, Pfizer, and others.
• Promising Hypertrophic Cardiomyopathy Pipeline Therapies in the various stages of development include Mavacamten, HRS-1893, Aficamten, IMB-1018972, TN-201, MYK-461, CK-3773274 (5- 15 mg), and others.

Hypertrophic Cardiomyopathy Country-based Treatment Analysis

The Hypertrophic Cardiomyopathy Treatment Market Report provides treatment regimens across the 7MM. It will help companies to analyze the practices followed across 7MM, the patient journey, and advances in Hypertrophic Cardiomyopathy therapies that have potential treatment paradigms and improve patient outcomes.

Hypertrophic Cardiomyopathy (HCM) is a common genetically inherited heart disease and represents an important cause of cardiovascular morbidity and mortality in patients of all ages. HCM is characterized by left ventricular hypertrophy unexplained by secondary causes and a no dilated left ventricle with preserved or increased ejection fraction. It is commonly asymmetrical, with the most severe hypertrophy involving the basal Intraventricular septum.

The current pharmacological treatment strategies of Hypertrophic Cardiomyopathy are mainly centered on managing and minimizing the symptoms. Pharmacotherapy is the most frequently used therapy for HCM, mostly obstructive HCM. The clinical intention is to manage symptoms related to LVOT obstruction. The mainstay of the therapy is a combination of three types of drugs: β-adrenergic antagonists, calcium channel blockers, and antiarrhythmic drugs.

Download the report to understand which factors are driving Hypertrophic Cardiomyopathy Epidemiology trends @ Hypertrophic Cardiomyopathy Epidemiology Forecast

Hypertrophic Cardiomyopathy Epidemiology Insights

In the assessment done by DelveInsight, the estimated total Hypertrophic Cardiomyopathy diagnosed prevalent cases in the 7MM was 239,797 in 2022. The highest Hypertrophic Cardiomyopathy diagnosed prevalent cases were accounted for by the US in 2022 which were approximately 48% of the 7MM. These cases are expected to increase during the forecast period (2023–2032).

Hypertrophic Cardiomyopathy Epidemiology Segmentation in the 7MM

• Hypertrophic Cardiomyopathy Prevalent Cases
• Hypertrophic Cardiomyopathy Gender-specific Diagnosed Prevalent Cases
• Hypertrophic Cardiomyopathy Diagnosed Prevalent Cases
• Hypertrophic Cardiomyopathy Type-specific Diagnosed Prevalent Cases

“As per DelveInsight’s assessments, males are more affected by Hypertrophic Cardiomyopathy than females. Also, the cases are projected to increase by 2032 in the United States”

Hypertrophic Cardiomyopathy Companies and Drugs

• Cytokinetics: CK-3773274 (5 mg, 10 mg, 15 mg and 20 mg)
• Bristol-Myers Squibb: Mavacamten
• Shandong Suncadia Medicine Co., Ltd.: HRS-1893
• MyoKardia Inc.: Mavacamten
• Imbria Pharmaceuticals Inc.: IMB-1018972
• Tenaya Therapeutics: TN-201

To learn more about Hypertrophic Cardiomyopathy Companies working in the treatment market, visit @ Hypertrophic Cardiomyopathy Clinical Trials and Therapeutic Assessment

Hypertrophic Cardiomyopathy Drugs Uptake

Aficamten (formerly CK-3773274, or CK-274) by Cytokinetics is an investigational, novel, oral, small molecule cardiac myosin inhibitor. Aficamten was granted Breakthrough Therapy Designation by the US FDA for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The US FDA also has granted orphan drug designation for Aficamten for the treatment of symptomatic HCM. Aficamten is a next-generation cardiac myosin inhibitor in development for the potential treatment of HCM currently undergoing Phase III clinical trials.

MYK-224 by Bristol-Myers Squibb is designed to preserve the unique advantages of mavacamten’s mechanism, including the ability to reduce excess contractility and potentially address impaired relaxation by reducing the number of engaged myosin-actin cross-bridges, while reducing pharmacokinetic variability. It is currently in Phase II of clinical trials for Obstructive Hypertrophic Cardiomyopathy.

Ninerafaxstat (IMB-1018972) by Imbria Pharmaceuticals, Inc. is an innovative treatment for cardiac diseases characterized by energy imbalance of the heart. Ninerafaxstat, a partial fatty acid oxidation (pFOX) inhibitor, is designed to shift myocardial substrate utilization in favor of glucose oxidation to generate more ATP per unit of oxygen consumed thereby increasing myocardial metabolic efficiency. Currently, Ninerafaxstat is in Phase II of clinical development for nHCM.

Hypertrophic Cardiomyopathy Emerging Therapy Assessment

Hypertrophic Cardiomyopathy companies across the globe are thoroughly working towards the development of novel treatment therapies in the HCM treatment landscape. There are several Hypertrophic Cardiomyopathy companies involved in the development of promising products such as Aficamten, MYK-224, and others.

Hypertrophic Cardiomyopathy Emerging Treatments

• Calcium channel blockers
• CAMZYOS (Mavacamten)
• MYK-224
• Aficamten

Discover more about therapies set to grab Major Hypertrophic Cardiomyopathy Market Share @ Hypertrophic Cardiomyopathy Treatment Market

Scope of the Hypertrophic Cardiomyopathy Market Research Report

• Coverage- 7MM
• Study Period- 2019-2032
• Forecast Period- 2023-2032
• Hypertrophic Cardiomyopathy Companies- Novartis, Imbria Pharmaceuticals, Cytokinetics, MyoKardia, Ji Xing Pharmaceuticals (Shanghai) Co. Ltd, Bristol-Myers Squibb, Shandong Suncadia Medicine Co., Ltd., MyoKardia Inc., Medtronic, GE Healthcare, Abbott Medical Devices, Tenaya Therapeutics, LianBio LLC, Gilead Sciences, LianBio LLC, Novartis Pharmaceuticals, iRhythm Technologies Inc., Amicus Therapeutics, Tau Pnu Medical Co. Ltd, Rocket Pharmaceuticals Inc., Edwards Lifesciences, Pfizer, and others.
• Hypertrophic Cardiomyopathy Pipeline Therapies- Mavacamten, HRS-1893, Aficamten, IMB-1018972, TN-201, MYK-461, CK-3773274 (5- 15 mg), and others.
• Hypertrophic Cardiomyopathy Market Dynamics: Hypertrophic Cardiomyopathy Market Drivers and Barriers

Note:-

DelveInsight's report offers comprehensive insights, market analysis, and forecasts aiding leading companies in strategic decision-making for the Hypertrophic Cardiomyopathy Market Landscape.

Gain Competitive Edge in the Indication Market: Understand the current landscape of the Hypertrophic Cardiomyopathy Market, including the competitive environment, key companies developing drugs for Hypertrophic Cardiomyopathy, and their strategies. By analyzing Hypertrophic Cardiomyopathy Market Dynamics, treatment approaches, and emerging therapies, stakeholders can identify opportunities to position themselves effectively, gaining a competitive edge over others.

Identify Market Gaps and indication market opportunities: Analyzing epidemiological trends, country-wise patient journeys, and existing treatment practices can help in identifying gaps and opportunities within the Hypertrophic Cardiomyopathy Market. This involves recognizing areas where current treatments may be insufficient or where there is Hypertrophic Cardiomyopathy unmet need. The report is curated by taking account of various KOLs dealing with Hypertrophic Cardiomyopathy. Identifying these gaps allows stakeholders to explore new therapeutic avenues, potentially leading to the development of novel treatments that address specific market needs and price their emerging products strategically to gain a competitive edge.

Strategic decision-making: Armed with insights from epidemiological and market forecasts, stakeholders can make informed and strategic decisions. This may involve deciding on research and development investments, portfolio expansion, pricing-reimbursement strategies, partnerships, or other strategic moves. Understanding the Hypertrophic Cardiomyopathy Market Dynamics enables stakeholders to align their goals with the prevailing trends and future projections.

Plan Roadmap to Success: Through this report, the leading Hypertrophic Cardiomyopathy Companies can set short-term and long-term goals, define strategies for market penetration, and outline steps for product development or market expansion. A well-informed roadmap ensures that stakeholders navigate the complexities of the Hypertrophic Cardiomyopathy Market with clarity and purpose.

Related Infographics:-

Hypertrophic Cardiomyopathy Market: Infographics

Related Reports

Hypertrophic Cardiomyopathy Epidemiology Forecast 2032

DelveInsight's Hypertrophic Cardiomyopathy (HCM) - Epidemiology Forecast 2032 report delivers an in-depth understanding of the disease, and historical, and forecasted epidemiology.

Hypertrophic Cardiomyopathy Pipeline Insight 2023

"Hypertrophic Cardiomyopathy Pipeline Insights, 2023" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects.

Explore Our Success Story of Building an Interactive Competitive Intelligence Dashboard for HR+ HER2- Breast Cancer Market Landscape. Download our Oncology Competitive Intelligence Case study! 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact 

Company Name: DelveInsight Business Research LLP

Contact Person: Yash Bhardwaj

Team Lead- Marketing

Email: info@delveinsight.com

Website: https://www.delveinsight.com/